Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus-Reference-Cited by-同舟云学术

Suppression of Serum Interferon‐γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus

Published:2021-02 Issue:3 Volume:73 Page:472-477
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Cesaroni Matteo¹,Seridi Loqmane¹^ORCID,Loza Matthew J.¹,Schreiter Jessica¹,Sweet Kristen¹,Franks Carol¹,Ma Keying¹,Orillion Ashley¹,Campbell Kim¹,M. Gordon Robert¹,Branigan Patrick¹,Lipsky Peter²,Vollenhoven Ronald³,Hahn Bevra H.⁴,Tsokos George C.⁵^ORCID,Chevrier Marc¹,Rose Shawn¹,Baribaud Frédéric¹,Jordan Jarrat⁶

Affiliation:

1. Janssen Research & Development, LLC Spring House Pennsylvania

2. AMPEL BioSolutions, LLC Charlottesville Virginia

3. Amsterdam Rheumatology and Immunology Center Amsterdam The Netherlands

4. University of California Los Angeles

5. Beth Israel Deaconess Medical Center and Harvard Medical School Boston Massachusetts

6. Janssen Research & Development, LLC Cambridge Massachusetts

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link